Targeting PI3K/MTOR signaling in cancer / / topic editor, Alexandre Arcaro.
The phosphatidylinositol 3-kinase (PI3K)/mTOR pathway integrates signals from growth factors with nutrient signals and other conditions and controls multiple cell responses, including proliferation, survival and metabolism. Deregulation of the PI3K pathway has been extensively investigated in connec...
Saved in:
: | |
---|---|
TeilnehmendeR: | |
Place / Publishing House: | [Lausanne, Switzerland] : : Frontiers Media SA,, 2014. |
Year of Publication: | 2014 |
Language: | English |
Series: | Frontiers Research Topics,
|
Physical Description: | 1 online resource (93 pages). |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993547388504498 |
---|---|
ctrlnum |
(CKB)3710000000504580 (WaSeSS)IndRDA00058636 (oapen)https://directory.doabooks.org/handle/20.500.12854/60490 (EXLCZ)993710000000504580 |
collection |
bib_alma |
record_format |
marc |
spelling |
Alexandre Arcaro auth Targeting PI3K/MTOR signaling in cancer / topic editor, Alexandre Arcaro. Frontiers Media SA 2014 [Lausanne, Switzerland] : Frontiers Media SA, 2014. 1 online resource (93 pages). text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics, 1664-8714 Includes bibliographical references. Description based on: online resource; title from pdf title page (frontiers, viewed Jun. 29, 2016). The phosphatidylinositol 3-kinase (PI3K)/mTOR pathway integrates signals from growth factors with nutrient signals and other conditions and controls multiple cell responses, including proliferation, survival and metabolism. Deregulation of the PI3K pathway has been extensively investigated in connection to cancer. Somatic or inherited mutations frequently occur in tumor suppressor genes (PTEN, TSC1/2, LKB1) and oncogenes (PIK3CA, PIK3R1, AKT) in the PI3K/mTOR pathway. The fact that the PI3K/mTOR pathway is deregulated in a large number of human malignancies, and its importance for different cellular responses, makes it an attractive drug target. Pharmacological PI3K inhibitors have played a very important role in studying cellular responses involving these enzymes. Currently, a wide range of selective PI3K inhibitors have been tested in preclinical studies and some have entered clinical trials in oncology. Rapamycin and its analogs targeting mTOR are effective in many preclinical cancer models. Although rapalogs are approved for the treatment of some cancers, their efficacy in clinical trials remains the subject of debate. Due to the complexity of the PI3K/mTOR signaling pathway, developing an effective anti-cancer therapy remains a challenge. The biggest challenge in curing cancer patients with various signaling pathway abnormalities is to target multiple components of different signal transduction pathways with mechanism-based combinatorial treatments. English Cancer. Phosphoinositides. Phosphoinositide 3-kinase mTOR clinical trials Akt Cancer 2-88919-244-X Arcaro, Alexandre, editor. |
language |
English |
format |
eBook |
author |
Alexandre Arcaro |
spellingShingle |
Alexandre Arcaro Targeting PI3K/MTOR signaling in cancer / Frontiers Research Topics, |
author_facet |
Alexandre Arcaro Arcaro, Alexandre, |
author_variant |
a a aa |
author2 |
Arcaro, Alexandre, |
author2_variant |
a a aa |
author2_role |
TeilnehmendeR |
author_sort |
Alexandre Arcaro |
title |
Targeting PI3K/MTOR signaling in cancer / |
title_full |
Targeting PI3K/MTOR signaling in cancer / topic editor, Alexandre Arcaro. |
title_fullStr |
Targeting PI3K/MTOR signaling in cancer / topic editor, Alexandre Arcaro. |
title_full_unstemmed |
Targeting PI3K/MTOR signaling in cancer / topic editor, Alexandre Arcaro. |
title_auth |
Targeting PI3K/MTOR signaling in cancer / |
title_new |
Targeting PI3K/MTOR signaling in cancer / |
title_sort |
targeting pi3k/mtor signaling in cancer / |
series |
Frontiers Research Topics, |
series2 |
Frontiers Research Topics, |
publisher |
Frontiers Media SA Frontiers Media SA, |
publishDate |
2014 |
physical |
1 online resource (93 pages). |
isbn |
2-88919-244-X |
issn |
1664-8714 |
callnumber-first |
R - Medicine |
callnumber-subject |
RC - Internal Medicine |
callnumber-label |
RC261 |
callnumber-sort |
RC 3261 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT alexandrearcaro targetingpi3kmtorsignalingincancer AT arcaroalexandre targetingpi3kmtorsignalingincancer |
status_str |
n |
ids_txt_mv |
(CKB)3710000000504580 (WaSeSS)IndRDA00058636 (oapen)https://directory.doabooks.org/handle/20.500.12854/60490 (EXLCZ)993710000000504580 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Targeting PI3K/MTOR signaling in cancer / |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1787548669249060864 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01256nam a2200313 i 4500</leader><controlfield tag="001">993547388504498</controlfield><controlfield tag="005">20160629112254.0</controlfield><controlfield tag="006">m o u </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">160629s2014 sz |||||o|||||||||||eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3710000000504580</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(WaSeSS)IndRDA00058636</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/60490</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993710000000504580</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">WaSeSS</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">WaSeSS</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC261</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Alexandre Arcaro</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Targeting PI3K/MTOR signaling in cancer /</subfield><subfield code="c">topic editor, Alexandre Arcaro.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2014</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">[Lausanne, Switzerland] :</subfield><subfield code="b">Frontiers Media SA,</subfield><subfield code="c">2014.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (93 pages).</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Frontiers Research Topics,</subfield><subfield code="x">1664-8714</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on: online resource; title from pdf title page (frontiers, viewed Jun. 29, 2016).</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The phosphatidylinositol 3-kinase (PI3K)/mTOR pathway integrates signals from growth factors with nutrient signals and other conditions and controls multiple cell responses, including proliferation, survival and metabolism. Deregulation of the PI3K pathway has been extensively investigated in connection to cancer. Somatic or inherited mutations frequently occur in tumor suppressor genes (PTEN, TSC1/2, LKB1) and oncogenes (PIK3CA, PIK3R1, AKT) in the PI3K/mTOR pathway. The fact that the PI3K/mTOR pathway is deregulated in a large number of human malignancies, and its importance for different cellular responses, makes it an attractive drug target. Pharmacological PI3K inhibitors have played a very important role in studying cellular responses involving these enzymes. Currently, a wide range of selective PI3K inhibitors have been tested in preclinical studies and some have entered clinical trials in oncology. Rapamycin and its analogs targeting mTOR are effective in many preclinical cancer models. Although rapalogs are approved for the treatment of some cancers, their efficacy in clinical trials remains the subject of debate. Due to the complexity of the PI3K/mTOR signaling pathway, developing an effective anti-cancer therapy remains a challenge. The biggest challenge in curing cancer patients with various signaling pathway abnormalities is to target multiple components of different signal transduction pathways with mechanism-based combinatorial treatments.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Phosphoinositides.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Phosphoinositide 3-kinase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mTOR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical trials</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Akt</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cancer</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88919-244-X</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arcaro, Alexandre,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-02-22 20:07:39 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2015-11-22 13:16:40 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338499140004498&Force_direct=true</subfield><subfield code="Z">5338499140004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338499140004498</subfield></datafield></record></collection> |